Cargando…

Clinical Significance of Protein Expression of Cyclooxygenase-2 and Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors

PURPOSE: This study was undertaken to evaluate the significance of cyclooxygenase-2 (COX2) overexpression and the expression of somatostatin receptor (SSTR) subtypes in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). MATERIALS AND METHODS: Two hundred and forty-seven cases of GEP-NET, compr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hee Sung, Lee, Hye Seung, Kim, Woo Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192880/ https://www.ncbi.nlm.nih.gov/pubmed/22022296 http://dx.doi.org/10.4143/crt.2011.43.3.181

Ejemplares similares

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Hee Sung, et al.
Publicado: (2014)

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
por: Wang, Yuhong, et al.
Publicado: (2017)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

Proposal for a Standardized Pathology Report of Gastroenteropancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
por: Cho, Mee-Yon, et al.
Publicado: (2013)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Liver transplantation in gastroenteropancreatic neuroendocrine tumors
por: Fernandes, Eduardo de Souza M., et al.
Publicado: (2023)

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
por: McClellan, Kristen, et al.
Publicado: (2022)

Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
por: Yoo, Changhoon, et al.
Publicado: (2021)

Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors
por: Gallicchio, Rosj, et al.
Publicado: (2023)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases
por: Zimmermann, Nadine, et al.
Publicado: (2018)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
por: Öberg, Kjell
Publicado: (2012)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression
por: Lu, Yao-Yao, et al.
Publicado: (2018)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results‐Medicare analysis of 5235 patients
por: Ni, Katherine, et al.
Publicado: (2021)

Altered miRNAs Expression Correlates With Gastroenteropancreatic Neuroendocrine Tumors Grades
por: Cavalcanti, Elisabetta, et al.
Publicado: (2020)

Clinical utility of lanreotide Autogel(®) in gastroenteropancreatic neuroendocrine tumors
por: Paragliola, Rosa Maria, et al.
Publicado: (2016)

Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy
por: Crabtree, Judy S.
Publicado: (2017)

Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective
por: Finnerty, Brendan M, et al.
Publicado: (2017)

Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors
por: Sansone, Andrea, et al.
Publicado: (2019)

Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
por: Grande, Enrique, et al.
Publicado: (2019)

Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
por: Barrea, Luigi, et al.
Publicado: (2021)

Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor
por: Song, Lili, et al.
Publicado: (2022)

Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study
por: Cho, Mee-Yon, et al.
Publicado: (2012)

Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells
por: Jo, HanHee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t3jclu5dvk7jbj0qroi9jgkati